It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries
The company has projected Rs. 5,630 crores of investment and to provide employment to 6,350 people in three phases over a period of eight years
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities
The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Aster commits to increase bed capacity in the State via capacity expansion and greenfield projects
Subscribe To Our Newsletter & Stay Updated
